Skip to main content

Advertisement

SpringerLink
Log in

Health-state utilities in long-term advanced melanoma survivors comparable with the general population

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Background

Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors.

Methods

Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores.

Results

Health-state utility scores were similar between the 24–36 months’- and the 36-plus months’ survival group (0.81 vs 0.86; p = .22). In survivors, lower utility scores were associated with symptoms of depression (β = − .82, p = .022) and fatigue burden (β = − .29, p = .007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p = .07).

Discussion

Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Hodi, F. S., et al. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(11), 1480–1492.

    Article  CAS  PubMed  Google Scholar 

  2. Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723.

    Article  CAS  PubMed  Google Scholar 

  3. Schadendorf, D., et al. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33(17), 1889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Albertini, M. R. (2018). The age of enlightenment in melanoma immunotherapy. Journal for Immunotherapy of Cancer, 6(1), 1–4.

    Article  Google Scholar 

  5. Rogiers, A., Boekhout, A., Schwarze, J. K., Awada, G., Blank, C. U., & Neyns, B. (2019). Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. Journal of Oncology. https://doi.org/10.1155/2019/5269062

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mamoor, M., Postow, M. A., Lavery, J. A., Baxi, S. S., Khan, N., Mao, J. J., Rogak, L. J., Sidlow, R., Thom, B., Wolchok, J. A., & Korenstein, D. (2020). Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. Journal for Immunotherapy of Cancer. https://doi.org/10.1136/jitc-2019-000260

    Article  PubMed  PubMed Central  Google Scholar 

  7. Boekhout, A. H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M. J., van den Eertwegh, A. J., Hospers, G. A., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., Ten Tije, A. J., & Piersma, D. (2021). Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncologica, 60(1), 69–77.

    Article  CAS  PubMed  Google Scholar 

  8. Rogiers, A., Leys, C., De Cremer, J., Awada, G., Schembri, A., Theuns, P., De Ridder, M., & Neyns, B. (2019). Longitudinal pilot study of the Health Related Quality of life, emotional burden and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab. Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-05168-3

    Article  PubMed  Google Scholar 

  9. Rogiers, A., Leys, C., De Cremer, J., Awada, G., Schembri, A., Theuns, P., De Ridder, M., & Neyns, B. (2020). Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. Journal of Immunology Research. https://doi.org/10.1007/s00520-019-05168-3

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lai-Kwon, J., et al. (2019). The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 13(4), 503–511.

    Article  PubMed  Google Scholar 

  11. Michael John Alex, G., & Wyrwich, K. W. (2003). Health utility measures and the standard gamble. Academic emergency medicine, 10(4), 360–363.

    Article  Google Scholar 

  12. Hatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12(1), 1–9.

    Article  Google Scholar 

  13. Reck, M., Taylor, F., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H., Orsini, L., & Gralla, R. J. (2018). Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non–small cell lung cancer: results from the CheckMate 017 study. Journal of Thoracic Oncology, 13(2), 194–204.

    Article  CAS  PubMed  Google Scholar 

  14. Hu, X., & Hay, J. W. (2018). First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer, 123, 166–171.

    Article  PubMed  Google Scholar 

  15. Miguel, L. S., Lopes, F. V., Pinheiro, B., Wang, J., Ruifeng, X., Pellissier, J., & Laires, P. A. (2017). Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value in Health, 20(8), 1065–1073.

    Article  PubMed  Google Scholar 

  16. Tromme, I., Devleesschauwer, B., Beutels, P., Richez, P., Leroy, A., Baurain, J.-F., Cornelis, F., Bertrand, C., Legrand, N., Degueldre, J., Thomas, L., Legrand, C., Lambert, J., Haagsma, J., & Speybroeck, N. (2014). Health-related quality of life in patients with melanoma expressed as utilities and disability weights. British Journal of Dermatology, 171(6), 1443–1450.

    Article  CAS  PubMed  Google Scholar 

  17. Randall Patrinely, J., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., Long, G. V., Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., & Johnson, D. B. (2021). Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma. JAMA oncology, 7(5), 744–748.

    Article  PubMed  Google Scholar 

  18. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Lance Cowey, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., … Hodi, S. (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma,". Journal of Clinical Oncology, 40(2), 127–137.

    Article  CAS  PubMed  Google Scholar 

  19. Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526.

    Article  CAS  PubMed  Google Scholar 

  20. van de Poll-Franse, L. V., Horevoorts, N., van Eenbergen, M., Denollet, J., Roukema, J. A., Aaronson, N. K., Vingerhoets, A., Coebergh, J. W., de Vries, J., Essink-Bot, M.-L., & Mols, F. (2011). The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. European Journal of Cancer, 47(14), 2188–2194.

    Article  PubMed  Google Scholar 

  21. Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5(1), 1–8.

    Article  Google Scholar 

  22. Feng, Y.-S., Kohlmann, T., Janssen, M. F., & Buchholz, I. (2021). Psychometric properties of the EQ-5D-5L: A systematic review of the literature. Quality of Life Research, 30(3), 647–673.

    Article  PubMed  Google Scholar 

  23. Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364.

    Article  CAS  PubMed  Google Scholar 

  24. Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.

    Article  CAS  PubMed  Google Scholar 

  25. Custers, J. A., van den Berg, S. W., van Laarhoven, H. W., Bleiker, E. M., Gielissen, M. F., & Prins, J. B. (2014). The cancer worry scale: Detecting fear of recurrence in breast cancer survivors. Cancer Nursing, 37(1), E44–E50.

    Article  PubMed  Google Scholar 

  26. Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003). The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 49(2), 156–163.

    Article  Google Scholar 

  27. Razali, N. M., & Wah, Y. B. (2011). Power comparisons of shapiro-wilk, kolmogorov-smirnov, lilliefors and anderson-darling tests. Journal of Statistical Modeling and Analytics, 2(1), 21–33.

    Google Scholar 

  28. Zhang, Z. (2016). Residuals and regression diagnostics: focusing on logistic regression. Annals of Translational Medicine. https://doi.org/10.21037/atm.2016.03.36

    Article  PubMed  PubMed Central  Google Scholar 

  29. Field, A. (2013). Discovering statistics using IBM SPSS statistics. Sage.

    Google Scholar 

  30. MacKinnon, D. P., Krull, J. L., & Lockwood, C. M. (2000). Equivalence of the mediation, confounding and suppression effect. Prevention science, 1(4), 173–181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Grandy, S., & Fox, K. M. (2008). EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Health and quality of life outcomes, 6(1), 1–7.

    Article  Google Scholar 

  32. Allaire, J. (2012). RStudio: Integrated development environment for R. Boston, MA, 770(394), 165–171.

    Google Scholar 

  33. Bates, D., Mächler, M., Bolker, B., & Walker, S. (2014). Fitting linear mixed-effects models using lme4. Journal of Statistical Software. https://doi.org/10.18637/jss.v067.i01

    Article  Google Scholar 

  34. J. S. Sekhon, 2008 Multivariate and propensity score matching software with automated balance optimization: the matching package for R. Journal of Statistical Software, Forthcoming

  35. Harries, M., Malvehy, J., Lebbe, C., Heron, L., Amelio, J., Szabo, Z., & Schadendorf, D. (2016). Treatment patterns of advanced malignant melanoma (stage III–IV)–a review of current standards in Europe. European Journal of Cancer, 60, 179–189.

    Article  PubMed  Google Scholar 

  36. Das, K. R., & Imon, A. (2016). A brief review of tests for normality. American Journal of Theoretical and Applied Statistics, 5(1), 5–12.

    Article  Google Scholar 

  37. Schielzeth, H., Dingemanse, N. J., Nakagawa, S., Westneat, D. F., Allegue, H., Teplitsky, C., Réale, D., Dochtermann, N. A., Garamszegi, L. Z., & Araya-Ajoy, Y. G. (2020). Robustness of linear mixed-effects models to violations of distributional assumptions. Methods in ecology and evolution, 11(9), 1141–1152.

    Article  Google Scholar 

  38. Lee, Y., & Nelder, J. A. (2004). Conditional and marginal models: another view. Statistical Science. https://doi.org/10.1214/088342304000000305

    Article  Google Scholar 

  39. Sprangers, M., & Schwartz, C. (1999). The challenge of response shift for quality-of-life-based clinical oncology research. Annals of oncology: Official Journal of the European Society for Medical Oncology, 10(7), 747–749.

    Article  CAS  PubMed  Google Scholar 

  40. Vosoughi, E., Lee, J. M., Miller, J. R., Nosrati, M., Minor, D. R., Abendroth, R., Lee, J. W., Andrews, B. T., Leng, L. Z., Max, W., Leong, S. P., Kashani-Sabet, M., & Kim, K. B. (2018). Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 18(1), 1–7.

    Article  Google Scholar 

  41. Spagnolo, F., Picasso, V., Lambertini, M., Ottaviano, V., Dozin, B., & Queirolo, P. (2016). Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. Cancer Treatment Reviews, 45, 38–45.

    Article  CAS  PubMed  Google Scholar 

  42. Dixon, S., Walters, S., Turner, L., & Hancock, B. (2006). Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial. British Journal of cancer, 94(4), 492–498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr. M. Hauptmann, Dr. W.E. Fiets, Dr. F.W. van den Berkmortel, Ms. S.H. Janssen (MSc), and Ms. C. Fokkema for their valuable contributions to this study.

Funding

This work was supported by Bristol-Myers Squibb under Protocol number CA209483. Bristol-Myers Squibb, CA209483, Annelies H Boekhout

Author information

Authors and Affiliations

  1. Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    M. D. Egeler, L. V. van de Poll-Franse, R. Tissier, V. P. Retèl & A. H. Boekhout

  2. Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    L. V. van de Poll-Franse

  3. Department of Medical and Clinical Psychology, Center of Research On Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands

    L. V. van de Poll-Franse

  4. Department of Psychiatry, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

    A. Rogiers

  5. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands

    M. J. Boers-Sonderen

  6. Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands

    A. J. van den Eertwegh

  7. Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands

    G. A. Hospers

  8. Isala Oncology Center, Zwolle, The Netherlands

    J. W. B. de Groot

  9. Department of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands

    M. J. B. Aarts

  10. Leiden University Medical Centre, Leiden, The Netherlands

    E. Kapiteijn

  11. Medical Spectrum Twente, Enschede, The Netherlands

    D. Piersma

  12. Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands

    G. Vreugdenhil

  13. Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands

    A. A. van der Veldt

  14. Department of Medical Oncology, University Medical Cancer Center, Utrecht, The Netherlands

    K. P. M. Suijkerbuijk

  15. Universitair Ziekenhuis Brussel, Brussels, Belgium

    B. Neyns

  16. Bristol-Myers Squibb, Utrecht, The Netherlands

    K. J. Janssen

  17. Department of Medical Oncology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    C. U. Blank

  18. Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

    V. P. Retèl

Authors
  1. M. D. Egeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. V. van de Poll-Franse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Tissier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Rogiers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. J. Boers-Sonderen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. J. van den Eertwegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. A. Hospers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. W. B. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. J. B. Aarts
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Kapiteijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D. Piersma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G. Vreugdenhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. A. van der Veldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K. P. M. Suijkerbuijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B. Neyns
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. K. J. Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. U. Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. V. P. Retèl
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A. H. Boekhout
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MDE, LVP, RT and AHB designed the study and wrote the study protocol. AR, MJB, AJE, GAH, JWBG, MJBA, EK, DP, GV, AAV, KMPS, EAR, BN and CUB recruited patients and collected data. AHB and LVP coordinated the study. MDE, AHB and RT did the statistical analyses. MDE, LVP, VR and AHB wrote the first draft of the manuscript. All authors interpreted the data, reviewed the manuscript, and approved the final version.

Corresponding author

Correspondence to M. D. Egeler.

Ethics declarations

Competing interests

A.H. Boekhout received a research grant from Bristol-Myers Squibb for this study. A. Rogiers: Bristol-Myers Squibb and Merck Sharp & Dome (consulting and advisory board). M. Boers-Sonderen: Bristol-Myers Squibb, Pierre Fabre, and Roch (advisory board). A.J.M. van den Eertwegh: Sanofi, Bristol-Myers Squibb and Roche (study grant); MSD Oncology, Roche, Pfizer, and Sanofi (travel expenses); Bristol-Myers Squibb (honoraria); Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, and Merck (advisory board). G.A. Hospers: Bristol-Myers Squibb, Amgen, Roche, Pfizer, Novartis, MSD (consulting and advisory board) and received research grants from Bristol-Myers Squibb and Seerave. J.W.B. de Groot: Bristol-Myers Squibb, MSD Oncology, Novartis, Pierre Fabre and Servier (consulting and advisory board). M.J.B. Aarts: Bristol-Myers Squibb, Merck Sharp & Dome, Pfizer, Pierre Fabre, Astellas, Ipsen and Novartis (consulting). K.P.M. Suijkerbuijk reports personal fees as a consult advisor (paid to institution) advisory role: Roche, Novartis, MSD, BMS, Pierre Fabre (all paid to institution). H.W. Kapiteijn: Amgen, Bristol-Myers Squibb, Novartis, Roche, Merck, Pierre-Fabre, EISAI, Bayer and Genzyme-Sanofi (consulting and advisory board); and received a research grant from Bristol-Myers Squibb. A.A.M. van der Veldt: Bayer (travel expenses) and Bristol-Myers Squibb, Merck Sharp & Dome, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Eisai and Ipsen (consulting and advisory board). K.J. Jansen is working at Bristol-Myers Squibb. B. Neyns: Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche (honoraria), and Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, Roche, Speakers’ Bureau-Novartis (consulting and advisory), and Amgen, Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche (travel expenses). C.U. Blank reports personal fees as a consultant advisor (paid to the institution) or travel support. All other authors declare no competing interests (Vreugdenhil, Tissier, Djura, and Retèl).

Ethical approval

The study was approved by the institutional review board of the NKI (METC16.0634) and meets the institutional review board standards.

Consent to participate

This study was performed in accordance with the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 39 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Egeler, M.D., van de Poll-Franse, L.V., Tissier, R. et al. Health-state utilities in long-term advanced melanoma survivors comparable with the general population. Qual Life Res 32, 2517–2525 (2023). https://doi.org/10.1007/s11136-023-03427-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-023-03427-9

Keywords

Search

Navigation